House cats may be far more useful to cancer research than scientists have shown so far.
In a study published in Science, researchers analyzed 493 matched tumor and normal tissue samples across 13 forms of feline cancer and identified 31 cancer driver genes, including several with clear parallels in human disease.
The findings do not establish a new treatment, but they give researchers an unusually broad genetic picture of cancers that develop naturally in cats.
The study also brings new attention to a longstanding research gap: feline cancer has remained relatively understudied at the genomic level, even as comparative cancer research in dogs has advanced much further.
Cats Are Finally Entering the Genomic Conversation
The dataset’s size marks a meaningful shift for a field that has historically had far less information on feline tumors than canine ones.
The researchers examined 493 matched tumor and normal samples representing 13 cancer types. Their targeted sequencing panel included 978 feline counterparts of genes already associated with human cancer.
From that analysis, they identified 31 cancer driver genes. TP53 was the most frequently mutated gene across the feline cancers, appearing in 33 percent of tumors.
The broader context is equally important. The paper notes that molecular research into canine cancers has advanced considerably, while previous next-generation sequencing studies of feline cancer were relatively few and often focused on smaller groups of animals or single tumor types.
Geoffrey Wood, a co-senior author from the University of Guelph, put the gap plainly: “There was very little known about the genetics of cancer in these animals, until now.”
Related: The 9 Smartest Cat Breeds, According to Experts
Why Naturally Occurring Cancer Changes the Research Question
Cats offer researchers a different biological setting from laboratory models because their cancers develop on their own rather than being deliberately engineered.
That does not make cats superior to laboratory mice, and the study does not claim that. It does suggest that naturally occurring cancers in companion animals may offer another useful point of comparison as scientists try to understand which cancer features are shared across species.
Several findings support that interest. TP53 mutations appeared in 33 percent of the feline cancers studied, while researchers also found recurring changes involving MYC, PTEN, and FAS.
Feline mammary cancer produced another notable set of findings. FBXW7 emerged as a major driver, and PIK3CA mutations were also common. PIK3CA is already well established in human cancer biology.
The similarities were not universal. Activating RAS mutations, common across human cancers, did not emerge as drivers in the feline tumor types studied. That difference matters because comparative oncology depends on understanding where species diverge, not just where they overlap.
Save this article
Enter your email address and we'll send it straight to your inbox.
Bailey Francis, a coauthor of the study, summarized the broader ambition: “When knowledge and data flow between different disciplines, we can all benefit.”
The Treatment Findings are Promising But Still Early
The study identified genetic changes connected to existing drugs, but the evidence remains at the research stage.
Researchers used human cancer and drug databases to examine whether mutations found in feline tumors were linked to existing treatments. Six of the 31 driver genes encoded proteins for which an approved drug exists in the database they consulted.
Those mutations appeared in 102 of the 493 tumors, or 21 percent. A separate analysis using the OncoKB database found that 67 tumors, or 14 percent, carried at least one oncogenic or likely oncogenic mutation in a potentially actionable driver gene.
The most direct treatment experiment involved laboratory-grown feline mammary tumor models. Researchers tested six lines: three with FBXW7 mutations and three without. The mutant lines were more sensitive to vincristine and vinorelbine.
The result is notable, but its limits are straightforward. It was not a clinical trial in cats or humans, and the researchers called for further study in larger groups.
Cats May Benefit Before Human Medicine Does
The clearest immediate value of the research may be a stronger foundation for understanding and eventually treating cancer in cats.
The new genetic map gives veterinary researchers a starting point for studying whether particular mutations could eventually inform diagnosis, prognosis or targeted treatment. Louise van der Weyden of the Wellcome Sanger Institute described the work as part of a path toward more precise feline oncology.
That possibility matters because much of the attention around the study has focused on what cats might contribute to human cancer research. The paper itself points in both directions.
One Medicine’s logic is that knowledge can move across species, not just from animals to humans. If feline cancers can be classified more precisely at the molecular level, cats could benefit from the same comparative framework that makes them scientifically useful.
The Next Chapter Depends On What the Data Can Actually Do
The study has opened a larger field of questions, but it has not answered whether feline cancer can reliably predict treatment outcomes in people.
Researchers still need to determine whether cats with particular mutations respond differently to treatment in real clinical settings. They also need to learn whether those responses have any dependable value for human oncology.
The current study has built-in limits. Its gene panel focused on feline counterparts of genes already linked to human cancer, which means it was designed around known human biology and may not capture every feline-specific cancer driver. Some individual cancer groups were also small, including only seven gliomas.
Still, the importance of the work does not depend on pretending those uncertainties are already resolved. For years, dogs have occupied much more of the genomic landscape in comparative oncology while cats remained comparatively underexamined. This study does not close that gap, but it gives scientists a serious reason to keep looking.
If one of the most familiar animals in American life has carried this much unexplored cancer biology beside us, what else have we failed to notice because no one mapped it closely enough?
